Effect of Cabergoline on Weight and Glucose Tolerance

Overview

The aim of this study is to determine the efficacy of cabergoline, a long-acting dopamine receptor agonist, on body weight and blood glucose in healthy obese adults. This is a randomized double-blind placebo controlled study. Twenty subjects each will be randomly assigned either placebo or cabergoline for 16 weeks. The effect of treatment on body weight and blood glucose and insulin levels will be compared in the treatment versus the placebo arm.

Full Title of Study: “Randomized Controlled Pilot Study of the Effect of Cabergoline on Body Weight and Glucose Tolerance in Healthy Obese Adults”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Masking: Double (Participant, Investigator)
  • Study Primary Completion Date: September 2003

Interventions

  • Drug: Cabergoline
    • cabergoline 0.5 mg twice weekly
  • Other: placebo
    • 1 pill twice weekly

Arms, Groups and Cohorts

  • Placebo Comparator: placebo
    • placebo pill
  • Active Comparator: cabergoline
    • cabergoline pill

Clinical Trial Outcome Measures

Primary Measures

  • body weight
    • Time Frame: 16 weeks

Secondary Measures

  • glucose
    • Time Frame: 16 weeks

Participating in This Clinical Trial

Inclusion Criteria

  • age 18 – 55 years – BMI 30 -40 Exclusion Criteria:

  • diabetes, – clinically significant medical condition, – use of medications that effect blood glucose or body weight

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 55 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Columbia University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Judith Korner, Associate Professor of Medicine – Columbia University
  • Overall Official(s)
    • Judith Korner, MD, PHD, Principal Investigator, Columbia University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.